Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate

PHASE1CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Contraception
Interventions
DRUG

EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo

Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.

DRUG

EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid

Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY